deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02718066

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)

Sponsor: HUYABIO International, LLC.

Conditions Melanoma Non-Small Cell Lung Cancer Renal Cell Carcinoma
Interventions HBI-8000 in combination with nivolumab
Updated 16 times since 2017 Last updated: Nov 8, 2023 Started: Aug 31, 2016 Primary completion: Sep 30, 2023 Completion: Sep 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Melanoma and Non-Small Cell Lung Cancer and is currently completed. HUYABIO International, LLC. leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Dec 2023 · 9 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jul 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2017 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • HUYABIO International, LLC.
Data source: HUYABIO International, LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations